| Equity |
EQUITY Accumulated Other Comprehensive Income (Loss)
The following table presents changes in the components of AOCI, net of taxes, for the nine months ended September 30, 2022:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Flow Hedge |
|
Foreign Currency Items |
|
Total |
|
(in thousands) |
| Balance at December 31, 2021 |
$ |
(8,558) |
|
|
$ |
(139,406) |
|
|
$ |
(147,964) |
|
Other comprehensive income before reclassifications |
50,178 |
|
|
(58,731) |
|
|
(8,553) |
|
| Amount reclassified from AOCI |
2,634 |
|
|
— |
|
|
2,634 |
|
| Net other comprehensive income |
52,812 |
|
|
(58,731) |
|
|
(5,919) |
|
| Balance at September 30, 2022 |
$ |
44,254 |
|
|
$ |
(198,137) |
|
|
$ |
(153,883) |
|
Earnings Per Share
Basic net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. The calculation of diluted net income (loss) per common share includes the effects of the assumed exercise of any outstanding stock options, the assumed vesting of shares of restricted and deferred stock awards and the assumed conversion of our convertible senior notes, where dilutive.
The following table sets forth the computation of weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
| Weighted average common shares—basic |
225,761,777 |
|
|
216,888,355 |
|
|
224,123,130 |
|
|
215,716,239 |
|
| Effect of dilutive securities: |
|
|
|
|
|
|
|
| Stock options and restricted stock |
6,060,991 |
|
|
6,912,045 |
|
|
7,409,515 |
|
|
— |
|
| Convertible senior notes |
11,864,035 |
|
|
— |
|
|
8,085,275 |
|
|
— |
|
| Weighted average common shares—diluted |
243,686,803 |
|
|
223,800,400 |
|
|
239,617,920 |
|
|
215,716,239 |
|
The following table shows securities excluded from the calculation of diluted net income (loss) per common share because such securities are anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
| Options to purchase shares of common stock |
3,750 |
|
|
3,750 |
|
|
3,750 |
|
|
7,727,064 |
|
| Restricted stock and deferred stock—unvested |
1,340,319 |
|
|
91,275 |
|
|
1,260,701 |
|
|
3,207,115 |
|
|
|
|
|
|
|
|
|
| Conversion shares related to the convertible senior notes |
— |
|
|
11,864,035 |
|
|
3,778,760 |
|
|
11,864,035 |
|
| Number of anti-dilutive potentially issuable shares excluded from diluted common shares outstanding |
1,344,069 |
|
|
11,959,060 |
|
|
5,043,211 |
|
|
22,798,214 |
|
|